BeOne Medicines AG (ONC) on Decifer

Decifer ranks ONC number 67 of 270 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 5% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 40% a year and profits grew 652% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• One of 3 precision oncology therapeutic suppliers with profits up 652% and momentum of 17 out of 35, though 5% returns keep it modest.

The current read

The evidence on ONC lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full ONC research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.